- Home
- NVS vs MRK Comparison
NVS vs MRK Comparison
Compare NVS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- MRK
- Stock Information
- Founded
- NVS 1895
- MRK 2000
- Country
- NVS Switzerland
- MRK United States
- Employees
- NVS N/A
- MRK N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- MRK Health Care
- Exchange
- NVS Nasdaq
- MRK Nasdaq
- Market Cap
- NVS 230.5B
- MRK 260.8B
- IPO Year
- NVS 1991
- MRK N/A
- Fundamental
- Price
- NVS $99.09
- MRK $99.27
- Analyst Decision
- NVS Hold
- MRK Buy
- Analyst Count
- NVS 6
- MRK 14
- Target Price
- NVS $121.25
- MRK $125.85
- AVG Volume (30 Days)
- NVS 1.1M
- MRK 10.5M
- Earning Date
- NVS 01-31-2025
- MRK 02-04-2025
- Dividend Yield
- NVS 3.81%
- MRK 3.26%
- EPS Growth
- NVS 130.53
- MRK 165.47
- EPS
- NVS 8.58
- MRK 4.78
- Revenue
- NVS $49,940,000,000.00
- MRK $63,174,000,000.00
- Revenue This Year
- NVS $10.04
- MRK $7.50
- Revenue Next Year
- NVS $4.55
- MRK $5.14
- P/E Ratio
- NVS $11.28
- MRK $20.76
- Revenue Growth
- NVS 8.92
- MRK 6.51
- 52 Week Low
- NVS $92.35
- MRK $94.48
- 52 Week High
- NVS $120.92
- MRK $134.63
- Technical
- Relative Strength Index (RSI)
- NVS 46.34
- MRK 46.23
- Support Level
- NVS $98.53
- MRK $98.05
- Resistance Level
- NVS $100.67
- MRK $102.97
- Average True Range (ATR)
- NVS 0.98
- MRK 1.60
- MACD
- NVS 0.54
- MRK 0.14
- Stochastic Oscillator
- NVS 65.73
- MRK 28.16
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.